Pamlab Joins Nestlé's Growing Heath-related Acquisitions
News of Nestlé Health Science’s latest acquisition came Tuesday with its agreement to purchase Pamlab, a medical foods manufacturer. For an undisclosed amount, the U.S.-based company – whose products treat patients with conditions like depression, diabetic peripheral neuropathy, dementia, and high-risk pregnancy – will be added to Nestlé’s portfolio, in line with its goals to expand into the health and nutrition industry.
“The acquisition of the Pamlab business is aligned with our strategic ambition to provide science-based nutritional solutions for people with chronic medical conditions,” Luis Cantarell, head of Nestlé Health Science, said in a statement.
As reported in Food Digital last summer, the world’s biggest food group is adapting to better meet the needs of a burgeoning customer base: a swiftly growing aging population. Since establishing Nestlé Health Science, a full own subsidiary of Nestlé in 2011, improving brain health has been at the forefront of the Swiss-based firm’s recent interests.
"Pamlab will particularly strengthen our brain health platform and provide us an additional foothold in metabolic health in the U.S.," said Cantarell. “By leveraging our nutrition heritage and US operations with Pamlab’s proven expertise in medical foods and strong sales force capabilities, together we can play a key role in helping to manage certain chronic diseases and improve the quality of patients’ lives.”
Nestlé: What Does “Good Food, Good Life” Mean to You?
Recent acquisitions by Nestlé include CM&D Pharma Ltd., maker of a chewing gum designed for patients with compromised kidney function, inflammatory bowel disease medication-maker Prometheus Laboratories, and another medical foods developer, Accera. Accera’s products include a “milk shake” to manage and improve symptoms of Alzheimer’s disease.
Tackling the treatment of diseases and conditions that often greatly reduce quality of life adds a whole new facet to the meaning of Nestlé’s long-standing motto: “Good Food, Good Life.”
“We are excited to join forces with Nestlé Health Science, and we share their commitment to personalized nutrition,” said Eric Wingerter, Pamlab President and Chief Executive Officer.
“With their support, we will accelerate the development and deployment of our innovative nutritional solutions for people with chronic metabolic and neurologic conditions. We are united by a common purpose, and a common culture, founded on our passion for patients to make a difference in people’s lives.”
Images sourced via Flickr: Nestlé
Birdie aims to reinvent elderly care with tech
British startup Birdie has announced it has raised £8.2 million to invest in innovation and scale up the business.
The company's announcement is timely as it follows the criticism of the UK government over their lack of a plan for social care, despite acknowledging the sector is in crisis - around a quarter of the UK's home care providers are on the brink of bankruptcy due to a lack of funds and staffing.
Birdie was born with a mission to "radically improve the lives of millions of older adults", by using app-based solutions, IoT and machine learning to put preventative care at the forefront. The company was founded by Max Parmentier, after experiencing his own frustrations with the care system - his grandfather struggled with the impact of life in a care home, but lacked any other option.
In 2017 Parmentier partnered with venture builder Kamet Ventures to set up Birdie, in a bid to fix this problem. Since then, Birdie has partnered with almost 500 providers across the UK, and supports more than 20,000 older people every week. In the past 12 months alone the number of people Birdie supports has got six times greater.
Birdie’s solution is an app to help care providers deliver more coordinated, personalised and preventative care, by giving them access to digital assessments, medication scheduling and planning tools. By using digital tools to take care of admin, staff have more time to spend with their care recipients.
The new investment will be used to fund Birdie’s next phase of growth in the UK, as the company scales to meet the rapidly growing demand of the aging population. The company will also invest in product innovation, creating new features to address customer requests.
In addition, Birdie is piloting new care models, including partnering with the NHS to identify COVID-19 symptoms, building predictive pharmacy models with AI, and helping health authorities to detect early warning signs of patients’ health risks.
Internally, Birdie is committed to having a progressive company ethos. All salaries are transparent, and staff work asynchronously to maximise flexibility and equity. Staff members also volunteer in their local community during office hours, and the company offsets all its emissions.
These efforts have led to numerous awards, including having the best SME culture in the UK, an Honorable Mention in the Health category of Fast Company’s 2021 World Changing Ideas Awards, and innovation in care at the LangBuisson awards.
“We believe the future of care for older people should be helping them to live at home for as long as possible through the delivery of personalised and preventative care" Parmentier said.
"Birdie is already the partner of choice for caregivers up and down the UK, and this new funding will help us rapidly increase the number we partner with and what we can offer them - meaning more people benefiting from more affordable, quality care. We’re proud of our mission and the values we embody to pursue it.”